Abstract: With advances in the intelligent-transportation-system technology of passenger information systems, the importance of even and clock headways in transit timetables is reduced. This allows ...
CIT and IFLI's partnership focuses on advancing SUMOylation-targeted therapies for follicular lymphoma, with IFLI committing up to $2.5 million. SUMOylation inhibition can reprogram tumor ...
Using eXoZymes' AI-driven exozymes platform, NCTx has demonstrated lab scale validation with 4 grams of NCT produced at a 96% yield and with a purity higher than 99%. NCT project went from concept to ...
First indication of stable, functional CAR-T cell generation in vivo using targeted lipid nanoparticles for DNA delivery WAYNE, Pa., & UTRECHT, Netherlands–(BUSINESS WIRE)–NanoCell Therapeutics, Inc. ...
Road names: Sunoco (NCTX [1967+] and UTLX [1974+] reporting marks), Canadian National company service (1985+), Government of Alberta (UTLX [1970+] and PROX [1983 ...
MONROVIA, CALIFORNIA / ACCESS Newswire / May 16, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into ...
Management to host earnings call at 5:00PM Eastern Time, today. MONROVIA, CA / ACCESS Newswire / May 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes ...
First quarter 2025, NCTx launch, and subsequent operational highlights: Commercialization: Launching purpose-built subsidiary, NCTx, to develop and commercialize the eXoZymes platform with the small ...
eXoZymes, a leader in AI-engineered enzymes, announced the creation of NCTx, LLC. This new subsidiary will develop and produce N-trans-caffeoyltyramine (NCT), a rare plant-based compound. NCT shows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback